Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
HeartBeam inc (BEAT)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-11-04
$0.39-6.93%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for BEAT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Improve cash from operations to reduce burn | HeartBeam shows early signs of improving losses and cash flow. | Intact | Cash from operations worsens below negative $3.6M next year | Cash from operations: $-3.342M FY2026-Q2; GAAP. Published target: Cash from operations improves to better than negative $3.6M. Target period is not explicitly aligned with this observation. Aug 13, 2026-3,342,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, high-risk healthcare business rather than an established compounder. The long-term thesis is on watch: recent performance is below its industry cohort, and the evidence snapshot gives low confidence.
The evidence does not provide a valuation measure or a clear account of market expectations, so whether the shares are cheap or expensive versus peers cannot be assessed. The business is loss-making, which makes expectations for improved profitability an important part of the thesis, but the evidence does not show how much of that improvement is already assumed.
Near term, management’s cost-focused restructuring has shown only limited progress: operating losses improved slightly between 2025-Q1 and 2026-Q2. Global licensing of the 3D ECG platform and work on heart attack detection are strategic priorities, but neither has measurable progress in the evidence, and the latter is not yet FDA cleared. The company remains loss-making, with high risk despite a recent decline in measured market risk.
Over the next one to three years, the thesis hinges on whether partnerships turn the 3D ECG platform into measurable adoption and whether the leaner structure improves operating results. Near term, weakening jobs data could weigh on cyclical healthcare names, while continued strength or weakness from sector bellwethers STE, QDEL, and MASS could support or erode the sector backdrop. Recent officer, debt, and legal or regulatory events add uncertainty, including a delisting-related notice.
BEAT’s multi-year view remains unproven: it is loss-making, and key initiatives lack measurable evidence of progress. The thesis depends on clearer execution and improved operating results amid high risk. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in HeartBeam inc's published investment case. The stated target is Stable leadership team with no further major departures. |
| Under Pressure |
| Additional key executive departures or leadership instability |
2 key executive departures (CEO, CFO) vs 0 allowed CEO and CFO departures confirmed in filings; Nasdaq deficiency notice received; stock down 27% in 21 days. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce operating losses toward break-even | Operating losses improved from negative $5.5M to negative $4.7M. | Intact | Operating income worsens below negative $4.7M next year | Operating income: $-5.092M FY2026-Q2; GAAP. Published target: Operating income improves to better than negative $4.7M. Target period is not explicitly aligned with this observation. Aug 13, 2026-5,092,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Advance commercial launch and product adoption | A supporting condition in HeartBeam inc's published investment case. The stated target is Sustained progress in product launches and adoption. | Under Pressure | No further progress in product launch or adoption | Q2 2026 earnings missed by $1.01; revenue fell short of estimates Q2 2026 earnings missed by $1.01 with revenue below estimates, despite FDA submission advances. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.28 → $-0.29 · observed estimates
$0.01B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.28 | $5,353,400 | 3 / 3 |
| 2026-07-25 | $-0.28 | $5,353,400 | 3 / 3 |
| 2026-07-26 | $-0.28 | $5,353,400 | 3 / 3 |
| 2026-07-27 | $-0.28 | $5,353,400 | 3 / 3 |
| 2026-07-28 | $-0.28 | $5,353,400 | 3 / 3 |
| 2026-07-29 | $-0.30 | $4,837,500 | 4 / 4 |
| 2026-07-30 | $-0.30 | $4,837,500 | 4 / 4 |
| 2026-07-31 | $-0.30 | $4,837,500 | 4 / 4 |
| 2026-08-01 | $-0.30 | $4,837,500 | 4 / 4 |
| 2026-08-02 | $-0.30 | $4,837,500 | 4 / 4 |
| 2026-08-03 | $-0.30 | $4,837,500 | 4 / 4 |
| 2026-08-04 | $-0.30 | $4,837,500 | 4 / 4 |
| 2026-08-05 | $-0.30 | $4,837,500 | 4 / 4 |
| 2026-08-06 | $-0.30 | $4,837,500 | 4 / 4 |
| 2026-08-07 | $-0.28 | $5,353,400 | 3 / 3 |
| 2026-08-08 | $-0.30 | $4,837,500 | 4 / 4 |
| 2026-08-09 | $-0.30 | $4,837,500 | 4 / 4 |
| 2026-08-10 | $-0.30 | $4,837,500 | 4 / 4 |
| 2026-08-11 | $-0.30 | $4,837,500 | 4 / 4 |
| 2026-08-12 | $-0.30 | $4,837,500 | 4 / 4 |
| 2026-08-13 | $-0.30 | $4,837,500 | 4 / 4 |
| 2026-08-14 | $-0.28 | $5,353,400 | 3 / 3 |
| 2026-08-15 | $-0.28 | $5,353,400 | 3 / 3 |
| 2026-08-16 | $-0.28 | $5,353,400 | 3 / 3 |
| 2026-08-17 | $-0.28 | $5,353,400 | 3 / 3 |
| 2026-08-18 | $-0.28 | $5,353,400 | 3 / 3 |
| 2026-08-19 | $-0.28 | $5,353,400 | 3 / 3 |
| 2026-08-20 | $-0.28 | $5,353,400 | 3 / 3 |
| 2026-08-21 | $-0.30 | $4,837,500 | 3 / 3 |
| 2026-08-22 | $-0.30 | $4,837,500 | 3 / 3 |
| 2026-08-23 | $-0.31 | $4,416,667 | 3 / 3 |
| 2026-08-24 | $-0.31 | $4,416,667 | 3 / 3 |
| 2026-08-25 | $-0.31 | $4,416,667 | 3 / 3 |
| 2026-08-26 | $-0.31 | $4,416,667 | 3 / 3 |
| 2026-08-27 | $-0.31 | $4,416,667 | 3 / 3 |
| 2026-08-28 | $-0.31 | $4,416,667 | 3 / 3 |
| 2026-08-29 | $-0.31 | $4,416,667 | 3 / 3 |
| 2026-08-30 | $-0.31 | $4,416,667 | 3 / 3 |
| 2026-08-31 | $-0.31 | $5,550,000 | 3 / 3 |
| 2026-09-01 | $-0.31 | $5,550,000 | 3 / 3 |
| 2026-09-02 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-03 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-04 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-05 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-06 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-07 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-08 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-09 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-10 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-11 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-12 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-13 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-14 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-15 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-16 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-17 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-18 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-19 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-20 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-21 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-22 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-23 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-24 | $-0.31 | $5,550,000 | 2 / 2 |
| 2026-09-25 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-09-26 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-09-27 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-09-28 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-09-29 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-09-30 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-01 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-02 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-03 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-04 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-05 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-06 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-07 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-08 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-09 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-10 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-11 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-12 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-13 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-14 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-15 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-16 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-17 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-18 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-19 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-20 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-21 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-22 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-23 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-24 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-25 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-26 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-27 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-28 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-29 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-30 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-10-31 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-11-01 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-11-02 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-11-03 | $-0.29 | $3,733,333 | 2 / 2 |
| 2026-11-04 | $-0.29 | $3,733,333 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.